Michael K Ameriks

This inventor holds 27 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Drug Modulation. Top assignees: Janssen Pharmaceutica Nv, Rapport Therapeutics, Inc.. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael K Ameriks. Retrieved from https://idiyas.com/inventor/michael-k-ameriks

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 11)

% Patents Active = 74.1

CIPO Patents = 3 (Patent Applications = 12)

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 16(Granted Patents)

Company Filing History:

26 out of 2,100

Janssen Pharmaceutica Nv

patents

1 out of 1

Rapport Therapeutics, Inc.

patent

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Monoacylglycerol Lipase

AMPA Receptor

Azaspirocycles

Aminocyclobutanes

Benzimidazoles

P2X7 Modulators

Indolone Compounds

Imidazopyrazines

Fused Azaheterocycles

Cyclobutyl Amides

Aryl Piperidines

Triazolo Compounds

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577243 - Monoacylglycerol lipase modulators (2026-03-17),

2. 12304908 - Azabenzimidazoles and their use as AMPA receptor modulators (2025-05-20),

3. 12145934 - Azabenzimidazoles and their use as AMPA receptor modulators (2024-11-19),

4. 12139485 - Azabenzimidazoles and their use as AMPA receptor modulators (2024-11-12),

5. 11993601 - Monoacylglycerol lipase modulators (2024-05-28),

6. 11919870 - Aminocyclobutanes as monoacylglycerol lipase modulators (2024-03-05),

7. 11897872 - Azaspirocycles as monoacylglycerol lipase modulators (2024-02-13),

8. 11891387 - Monoacylglycerol lipase modulators (2024-02-06),

9. 11820766 - Monoacylglycerol lipase modulators (2023-11-21),

10. 11802111 - Cyclobutyl amide monoacylglycerol lipase modulators (2023-10-31),

11. 11787798 - Aryl piperidines as monoacylglycerol lipase modulators (2023-10-17),

12. 11708359 - Monoacylglycerol lipase modulators (2023-07-25),

13. 11597728 - Monoacylglycerol lipase modulators (2023-03-07),

14. 11512059 - Aminocyclobutanes as monoacylglycerol lipase modulators (2022-11-29),

15. 11505546 - Azaspirocycles as monoacylglycerol lipase modulators (2022-11-22),

Title: The Innovative Mind of Michael K Ameriks

Introduction:

Michael K Ameriks is a prolific inventor based in San Diego, CA, with an impressive portfolio of 22 patents to his name. His groundbreaking work in the field of pharmaceuticals has had a significant impact on various disease states and conditions associated with MGL modulation.

Latest Patents:

Among his latest patents are "Aminocyclobutanes as monoacylglycerol lipase modulators" and "Azaspirocycles as monoacylglycerol lipase modulators." These compounds have paved the way for novel pharmaceutical compositions aimed at treating a wide range of disorders including pain, psychiatric disorders, neurological disorders, cancers, and eye conditions.

Career Highlights:

Michael K Ameriks is currently affiliated with Janssen Pharmaceutica Nv, a leading pharmaceutical company known for its innovative research and development efforts. His work at Janssen Pharmaceutica Nv has showcased his dedication to advancing the field of medicine through cutting-edge inventions and patents.

Collaborations:

Throughout his career, Michael K Ameriks has collaborated with esteemed professionals in the industry. Notable coworkers include Suchitra Ravula and Brian Ngo Laforteza, who have contributed to the success of his innovative projects and patents.

Conclusion:

In conclusion, Michael K Ameriks stands out as a visionary inventor whose contributions have revolutionized the pharmaceutical landscape. His relentless pursuit of innovation and collaboration with industry experts have solidified his position as a key figure in the world of patent applications and inventions.

Profile summary based on public USPTO records.